LRP5 and vitreoretinal degeneration: Already in early studies on LRP5 and OPPG, and in many studies thereafter, it has been noticed that carriers of heterozygous rare LRP5 variants also have reduced bone mass but usually lack eye manifestations or may have a milder eye phenotype in the form of vitreoretinopathy [34, 44, 48].